With $150M and a new NASH dis­cov­ery deal with Gilead, AI star Daphne Koller has set out to change the drug R&D world

Daphne Koller spent the last year qui­et­ly putting to­geth­er one of the biggest plays in bio­phar­ma AI. And backed by some of the deep­est pock­ets in biotech, she’s now mark­ing a key turn­ing point for her fledg­ling start­up in­sitro by form­ing a fresh R&D al­liance with Gilead.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER